Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033743 · ClinicalTrials.gov registry record · Phase 2
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT05033743 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 24 participants.
The verdict
NCT05033743, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.
Interventions
- DRUG Secnidazole 2 GM Oral Granules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-07-09 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05033743
The ClinicalTrials.gov registry entry for NCT05033743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secnidazole 2 GM Oral Granules is the first listed.
NCT05033743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05033743 about?
NCT05033743 is a clinical study titled "Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study". The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.
What is the current status of trial NCT05033743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-07-09. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT05033743?
The interventions under investigation include: Secnidazole 2 GM Oral Granules (DRUG).
Who is sponsoring clinical trial NCT05033743?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.